Compare ARBK & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARBK | AYTU |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 20.5M |
| IPO Year | 2021 | N/A |
| Metric | ARBK | AYTU |
|---|---|---|
| Price | $0.21 | $2.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $9.17 |
| AVG Volume (30 Days) | ★ 1.6M | 52.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,043,000.00 | ★ $63,696,000.00 |
| Revenue This Year | $183.90 | N/A |
| Revenue Next Year | $26.78 | $47.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.95 |
| 52 Week High | $1.12 | $2.82 |
| Indicator | ARBK | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 48.39 |
| Support Level | $0.20 | $1.91 |
| Resistance Level | $0.27 | $2.18 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 9.26 | 46.84 |
Argo Blockchain PLC is a blockchain technology company focused on the large-scale mining of Bitcoin. It mines bitcoin using purpose-built computers (or mining machines) to solve complex cryptographic algorithms on the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company acquires and deploys mining technology solutions in North American facilities that utilize predominantly renewable and inexpensive electricity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.